DOI:
10.1055/s-00000054
Pharmacopsychiatry
LinksClose Window
References
Preskorn SH, Baker B, Kolluri S. et al.
An innovative design to establish proof of concept of the antidepressant effects
of the NR2B subunit selective n-methyl-d-aspartate antagonist, CP-101,606, in
patients with treatment-refractory major depressive disorder.
J Clin Psychopharmacol 2008;
28: 631-637
We do not assume any responsibility for the contents of the web pages of other providers.